A18i Capital Ltd,
17/F Glenealy Tower,
No. 1 Glenealy, Central, Hong Kong
Science-driven healthcare expertise
Hands-on value creation
Investment in disruptive research
Co-Founder
Daniel previously worked as M&A investment banker (Evercore), management consultant (Roland Berger) and CEO in the diagnostics industry. Daniel holds a Masters of Management from the London School of Economics and also studied at TU Darmstadt and the Hong Kong University of Science and Technology.
The A18i Capital team joined NeraCare GmbH in 2017 as investors and operating managers and has been leading the company’s strategy and operations since.
Through the leadership of A18i, NeraCare has raised US$10m+ in funding and its main product MelaGenix was used in a landmark clinical trail "NivoMela".
2017
A18i Capital invested into NeraCare GmbH in 2017
$10M
NeraCare has raised $10m US
A18i Capital Ltd,
17/F Glenealy Tower,
No. 1 Glenealy, Central, Hong Kong